David A. Siegel Novo Nordisk A S Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Novo Nordisk A S stock. As of the latest transaction made, Two Sigma Advisers, LP holds 136,400 shares of NVO stock, worth $11.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

136,400

Previous 158,900 14.16%

Holding current value

$11.9 Million

Previous $22.7 Million 28.39%

% of portfolio

0.04%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $2.68 Million - $3.27 Million	-22,500 Reduced 14.16%	136,400 $16.2 Million
Q2 2024 Aug 14, 2024	BUY	$122.71 - $146.91 $2.29 Million - $2.75 Million	18,700 Added 13.34%	158,900 $22.7 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $245,064 - $326,207	2,400 Added 1.74%	140,200 $18 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $1.24 Million - $1.49 Million	14,100 Added 11.4%	137,800 $14.3 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $3.59 Million - $7.88 Million	39,500 Added 46.91%	123,700 $11.2 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $11.2 Million - $12.4 Million	72,000 Added 590.16%	84,200 $13.6 Million
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $436,722 - $525,162	-3,300 Reduced 21.29%	12,200 $1.94 Million
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $1.44 Million - $1.89 Million	-14,000 Reduced 47.46%	15,500 $2.1 Million
Q3 2022 Nov 14, 2022	SELL	$95.28 - $116.93 $25.9 Million - $31.8 Million	-271,900 Reduced 90.21%	29,500 $2.94 Million
Q2 2022 Aug 15, 2022	SELL	$103.24 - $121.81 $8.73 Million - $10.3 Million	-84,600 Reduced 21.92%	301,400 $33.6 Million
Q1 2022 May 16, 2022	SELL	$93.1 - $112.54 $27.1 Million - $32.7 Million	-290,600 Reduced 42.95%	386,000 $42.9 Million
Q4 2021 Feb 14, 2022	SELL	$95.88 - $117.08 $3.77 Million - $4.6 Million	-39,300 Reduced 5.49%	676,600 $75.8 Million
Q3 2021 Nov 15, 2021	BUY	$84.42 - $106.62 $46.9 Million - $59.2 Million	555,300 Added 345.77%	715,900 $68.7 Million
Q2 2021 Aug 16, 2021	BUY	$67.66 - $84.76 $4.03 Million - $5.04 Million	59,500 Added 58.85%	160,600 $13.5 Million
Q1 2021 May 17, 2021	BUY	$67.06 - $75.82 $4.72 Million - $5.34 Million	70,400 Added 229.32%	101,100 $6.82 Million
Q4 2020 Feb 16, 2021	SELL	$63.89 - $73.8 $18.4 Million - $21.3 Million	-288,000 Reduced 90.37%	30,700 $2.14 Million
Q3 2020 Nov 16, 2020	BUY	$63.69 - $70.22 $5.02 Million - $5.53 Million	78,800 Added 32.85%	318,700 $22.1 Million
Q2 2020 Aug 14, 2020	BUY	$58.54 - $67.94 $9.66 Million - $11.2 Million	165,100 Added 220.72%	239,900 $15.7 Million
Q1 2020 May 15, 2020	SELL	$49.46 - $64.78 $3.14 Million - $4.11 Million	-63,500 Reduced 45.91%	74,800 $4.5 Million
Q4 2019 Feb 14, 2020	BUY	$49.86 - $58.26 $6.9 Million - $8.06 Million	138,300 New	138,300 $8.01 Million
Q2 2019 Aug 14, 2019	SELL	$46.79 - $52.47 $753,319 - $844,767	-16,100 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$46.36 - $52.63 $12.2 Million - $13.8 Million	-262,200 Reduced 94.21%	16,100 $842,000
Q4 2018 Feb 14, 2019	BUY	$41.54 - $47.25 $10.4 Million - $11.8 Million	250,400 Added 897.49%	278,300 $12.8 Million
Q3 2018 Nov 14, 2018	BUY	$46.76 - $51.24 $1.3 Million - $1.43 Million	27,900 New	27,900 $1.32 Million
Q2 2018 Aug 14, 2018	SELL	$44.29 - $50.42 $2.48 Million - $2.82 Million	-56,000 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$48.49 - $58.14 $10.3 Million - $12.4 Million	-213,100 Reduced 79.19%	56,000 $2.76 Million
Q4 2017 Feb 14, 2018	SELL	$47.53 - $53.73 $10.3 Million - $11.7 Million	-217,200 Reduced 44.66%	269,100 $14.4 Million
Q3 2017 Nov 14, 2017	BUY	$41.15 - $49.22 $20 Million - $23.9 Million	486,300	486,300 $23.4 Million

Others Institutions Holding NVO

# of Institutions

1,957

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account